9
DMARD, disease-modifying antirheumatic drug ; HCQ, hydroxychloroquine; LEF, leflunomide;
MTX, methotrexate; NSAIDs, non-steroid anti-inflammatories; SSZ, sulfasalazine; TMJ,
temporomandibular joint
Risk factors, such as:
• involvement of ankle, wrist, hip and/or TMJ
• presence of erosive disease
• delay in diagnosis
• elevated inflammatory markers
• symmetric disease
Use of validated disease activity measures,
especially to facilitate treat-to-target approaches.
Presentation
Disease status decision point
Assessed disease status
Treatment option,
Conditional recommendation
Treatment option,
Strong recommendation
Additional considerations to guide treatment
decisions for JIA with oligoarthritis:
